IL231957A0 - New immune system modulators based on imidazole quinoline - Google Patents

New immune system modulators based on imidazole quinoline

Info

Publication number
IL231957A0
IL231957A0 IL231957A IL23195714A IL231957A0 IL 231957 A0 IL231957 A0 IL 231957A0 IL 231957 A IL231957 A IL 231957A IL 23195714 A IL23195714 A IL 23195714A IL 231957 A0 IL231957 A0 IL 231957A0
Authority
IL
Israel
Prior art keywords
immune system
based immune
imidazole quinoline
novel imidazole
system modulators
Prior art date
Application number
IL231957A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janus Biotherapeutics Inc
Lipford Grayson B
Zepp Charles M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janus Biotherapeutics Inc, Lipford Grayson B, Zepp Charles M filed Critical Janus Biotherapeutics Inc
Publication of IL231957A0 publication Critical patent/IL231957A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL231957A 2011-10-04 2014-04-06 New immune system modulators based on imidazole quinoline IL231957A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161543082P 2011-10-04 2011-10-04
PCT/US2012/058566 WO2013052550A2 (en) 2011-10-04 2012-10-03 Novel imidazole quinoline-based immune system modulators

Publications (1)

Publication Number Publication Date
IL231957A0 true IL231957A0 (en) 2014-05-28

Family

ID=48044383

Family Applications (1)

Application Number Title Priority Date Filing Date
IL231957A IL231957A0 (en) 2011-10-04 2014-04-06 New immune system modulators based on imidazole quinoline

Country Status (8)

Country Link
US (1) US9873694B2 (en:Method)
EP (1) EP2763677B1 (en:Method)
JP (1) JP2014528449A (en:Method)
AU (1) AU2012318694B2 (en:Method)
CA (1) CA2850932A1 (en:Method)
IL (1) IL231957A0 (en:Method)
IN (1) IN2014KN00948A (en:Method)
WO (1) WO2013052550A2 (en:Method)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
KR102506321B1 (ko) 2016-07-30 2023-03-03 브리스톨-마이어스 스큅 컴퍼니 Tlr7, tlr8 또는 tlr9 억제제로서의 디메톡시페닐 치환된 인돌 화합물
US10660877B2 (en) 2016-09-09 2020-05-26 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
JP7266576B2 (ja) 2017-08-04 2023-04-28 ブリストル－マイヤーズ スクイブ カンパニー ［１，２，４］トリアゾロ［４，３－ａ］ピリジニル置換のインドール化合物
JP7104775B2 (ja) 2017-08-04 2022-07-21 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ７／８／９の阻害剤として有用な置換インドール化合物
US20210253593A1 (en) 2017-11-14 2021-08-19 Bristol-Myers Squibb Company Substituted indole compounds
AU2018386201A1 (en) 2017-12-15 2020-07-30 Bristol-Myers Squibb Company Substituted indole ether compounds
WO2019125977A1 (en) 2017-12-18 2019-06-27 Bristol-Myers Squibb Company 4-azaindole compounds
WO2019126082A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company 6-azaindole compounds
CA3085346A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Amide substituted indole compounds useful as tlr inhibitors
US11878975B2 (en) 2017-12-19 2024-01-23 Bristol-Myers Squibb Company Substituted indole compounds useful as TLR inhibitors
ES2904773T3 (es) 2017-12-20 2022-04-06 Bristol Myers Squibb Co Compuestos de diazaindol
KR102714788B1 (ko) 2017-12-20 2024-10-08 브리스톨-마이어스 스큅 컴퍼니 Tlr 억제제로서 유용한 아미노 인돌 화합물
WO2019126253A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
ES2963696T3 (es) 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
WO2020086503A1 (en) 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole and indazole compounds
CN113811299A (zh) * 2019-03-15 2021-12-17 博笛生物科技有限公司 用于治疗癌症的免疫调控性组合物和方法
WO2020227484A1 (en) 2019-05-09 2020-11-12 Bristol-Myers Squibb Company Substituted benzimidazolone compounds
WO2021067326A1 (en) 2019-10-01 2021-04-08 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
EP4038059B1 (en) 2019-10-04 2023-09-20 Bristol-Myers Squibb Company Substituted carbazole compounds
US11530218B2 (en) 2020-01-20 2022-12-20 Incyte Corporation Spiro compounds as inhibitors of KRAS
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
WO2022204112A1 (en) 2021-03-22 2022-09-29 Incyte Corporation Imidazole and triazole kras inhibitors
EP4323369A1 (en) 2021-04-16 2024-02-21 Gilead Sciences, Inc. Thienopyrrole compounds
MX2024000357A (es) 2021-07-07 2024-02-12 Incyte Corp Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
JP2024534187A (ja) 2021-08-31 2024-09-18 インサイト・コーポレイション Ｋｒａｓの阻害剤としてのナフチリジン化合物
CN117957234A (zh) 2021-09-10 2024-04-30 吉利德科学公司 噻吩并吡咯化合物
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
WO2023056421A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
MX2024004444A (es) 2021-10-14 2024-05-08 Incyte Corp Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras).

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1271477A (en) * 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
AR006928A1 (es) 1996-05-01 1999-09-29 Pioneer Hi Bred Int Una molecula de adn aislada que codifica una proteina fluorescente verde como marcador rastreable para la transformacion de plantas, un metodo para laproduccion de plantas transgenicas, un vector de expresion, una planta transgenica y celulas de dichas plantas.
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
DE69841122D1 (de) 1997-03-10 2009-10-15 Coley Pharm Gmbh Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
ATE348157T1 (de) 1997-05-07 2007-01-15 Schering Corp Menschliche toll-ähnliche rezeptorproteine, zugehörige reagenzien und verfahren
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
AU3884199A (en) 1998-05-06 1999-11-23 Ottawa Health Research Institute Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
CA2359115C (en) 1999-01-22 2011-06-21 Elan Pharmaceuticals, Inc. Acyl derivatives which treat vla-4 related disorders
ATE333284T1 (de) 1999-09-27 2006-08-15 Coley Pharm Group Inc Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon
CA2410082A1 (en) 2000-05-25 2001-11-29 Schering Corporation Dnax toll-like receptor 7 (dtlr7) protein, related reagents and methods
MXPA04001458A (es) 2001-08-17 2005-02-17 Univ Iowa Res Found Oligonucleotidos inmunoestimuladores de motivos combinados con actividad mejorada.
WO2005016235A2 (en) * 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
KR20060016817A (ko) * 2003-06-20 2006-02-22 콜리 파마슈티칼 게엠베하 소분자 톨-유사 수용체 (ｔｌｒ) 길항제
WO2006091567A2 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
JP5247458B2 (ja) * 2005-11-04 2013-07-24 スリーエム・イノベイティブ・プロパティーズ・カンパニー ヒドロキシ及びアルコキシ置換１ｈ−イミダゾキノリン及び方法
US20100010217A1 (en) * 2006-03-23 2010-01-14 Valiante Nicholas M Methods for the preparation of imidazole-containing compounds
US8027888B2 (en) * 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
US7943771B2 (en) * 2007-01-24 2011-05-17 Chemagis Ltd. Imiquimod production process
HUE031307T2 (hu) * 2007-01-31 2017-07-28 Chongxi Yu 1H-imidazo[4,5-C]kinolin-4-aminok és rokon vegyületek pozitív töltésû vízoldható prodrugjai, amelyek nagyon magas bõr-penetrációs sebességekkel rendelkeznek
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
KR20110095857A (ko) 2008-09-10 2011-08-25 칼립시스, 인코포레이티드 질환의 치료를 위한 히스타민 수용체의 헤테로시클릭 억제제
JP2013512859A (ja) * 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
US8728486B2 (en) * 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds

Also Published As

Publication number Publication date
AU2012318694B2 (en) 2016-12-22
CA2850932A1 (en) 2013-04-11
EP2763677A2 (en) 2014-08-13
US20140242121A1 (en) 2014-08-28
WO2013052550A3 (en) 2014-05-15
IN2014KN00948A (en:Method) 2015-08-21
AU2012318694A1 (en) 2014-05-22
EP2763677A4 (en) 2015-05-20
EP2763677B1 (en) 2020-02-26
WO2013052550A2 (en) 2013-04-11
US9873694B2 (en) 2018-01-23
JP2014528449A (ja) 2014-10-27

Similar Documents

Publication Publication Date Title
IL231957A0 (en) New immune system modulators based on imidazole quinoline
IL229541A0 (en) New immune system modulators
SG11201400645TA (en) Communication system
GB201112752D0 (en) Communication system
GB201116924D0 (en) Communication system
IL260977B (en) communication system
ZA201400611B (en) Shelf-monitoring system
EP2720442A4 (en) COMMUNICATION SYSTEM
GB201102883D0 (en) Communication system
GB201113943D0 (en) Communication system
GB201119207D0 (en) Communication system
GB201113942D0 (en) Communication system
GB201109100D0 (en) Transmission system
EP2719500A4 (en) PART PROCESSING SYSTEM
PL2785385T3 (pl) Sprzęt gospodarstwa domowego z systemem dezodoryzującym
GB2491044B (en) Ablutionary system
GB201120956D0 (en) Communication system
ZA201401657B (en) Pimping system
GB2495002B (en) Connection system
GB201120963D0 (en) Communication system
GB201113939D0 (en) Communication system
EP2757828A4 (en) COMMUNICATION SYSTEM
PL2741811T3 (pl) Układ do leczenia objawów
PL2872583T3 (pl) Układ adhezyjny
LT2731976T (lt) Klijų kompozicija